Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665128 | 0.85 | CLK2 (0.33) | — | |
| SCHEMBL17642615 | 0.85 | CLK2 (0.33) | — | |
| SCHEMBL12589480 | 0.85 | CLK2 (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL2912962 | 0.73 | GABRP (0.39) | PKMHRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL16874638 | 0.73 | KDM1A (0.47) | — | |
| SCHEMBL20179833 | 0.72 | GABRA5 (0.34) | SSTR4 | |
| SCHEMBL28402574 | 0.71 | — | — | |
| SCHEMBL18018422 | 0.71 | CLK2 (0.32) | — | |
| SCHEMBL28737330 | 0.70 | — | — | |
| Trifluoroacetic Acid SCHEMBL4044054 | 0.70 | CHRNB2 (0.35) | PKMSSTR4HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| EP-3508483-B1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-109790145-B | Dihydropyrimidine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20200253971-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| US-10696669-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-20190225603-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3508483-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, DHPS, HPRT1 | PKM 1075/4885SSTR4 4659/4885HRH4 462/4885 |
| US-20190225603-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | DPYD, TYMP, DHPS | PKM 1106/4885SSTR4 4650/4885HRH4 1186/4885 |
| US-20200253971-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | DPYD, DHPS, HPRT1 | PKM 1075/4885SSTR4 4659/4885HRH4 462/4885 |
| US-10696669-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, TYMP, DHPS | PKM 1106/4885SSTR4 4650/4885HRH4 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.